Qiagen ( (QGEN) ) has issued an update.
QIAGEN N.V. announced a managerial transaction involving Thierry Bernard, a member of its managing body, who released 850 Performance Stock Units granted in 2015. Following the release, Bernard received 434 Common Shares after net share settlement, with some shares withheld by the company to cover related expenses. This transaction reflects the company’s ongoing commitment to aligning managerial interests with shareholder value, potentially impacting stakeholder confidence and market perception.
More about Qiagen
QIAGEN N.V. is a prominent player in the biotechnology industry, specializing in the development and distribution of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company is known for its focus on providing solutions that enable customers to gain valuable insights from the building blocks of life, DNA, RNA, and proteins.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.